Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related LHCG
Top 4 Stocks In The Home Health Care Industry With The Highest EPS
Top Performing Industries For February 26, 2015
LHC Group's (LHCG) CEO Keith Myers on Q4 2014 Results - Earnings Call Transcript (Seeking Alpha)
Related GEVA
Wedbush Securities Sees Preparations Continuing For Expected Approval And Strong Launch Of Kanuma For Synageva Biopharma
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
Synageva BioPharma's (GEVA) CEO Sanj Patel on Q4 2014 Results - Earnings Call Transcript (Seeking Alpha)

Analysts at Deutsche Bank downgraded LHC Group (NASDAQ: LHCG) from “buy” to “hold.” The target price for LHC Group is set to $23. LHC Group's shares closed at $23.36 yesterday.

Analysts at JP Morgan downgraded Synageva BioPharma (NASDAQ: GEVA) from “overweight” to “neutral.” The target price for Synageva BioPharma has been lowered from $57 to $50. Synageva BioPharma's shares closed at $45.79 yesterday.

Analysts at Canaccord Genuity downgraded Rent-A-Center (NASDAQ: RCII) from “buy” to “hold.” The target price for Rent-A-Center has been lowered from $42.00 to $37.00. Rent-A-Center's shares closed at $35.80 yesterday.

McNicoll Lewis Vlak downgraded Transcept Pharmaceuticals (NASDAQ: TSPT) from “buy” to “hold.” The target price for Transcept Pharmaceuticals is set to $3. Transcept Pharmaceuticals' shares closed at $3.09 yesterday.

Latest Ratings for LHCG

DateFirmActionFromTo
Feb 2015Credit SuisseMaintainsOutperform
Dec 2014Credit SuisseUpgradesUnderperformOutperform
Nov 2014BairdUpgradesUnderperformNeutral

View More Analyst Ratings for LHCG
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (LHCG + GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga PRO content